The Food and Drug Administration (FDA) has approved the first artificial intelligence tool to predict breast cancer risk. The image-based prognostic platform is designed to predict five-year breast ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

The designation qualifies CERo and CER-1236 for certain incentives, such as FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval ...

Kraft Heinz plans to remove artificial dyes from its U.S. products starting in 2027 and will no longer launch new products with the dyes. In a statement ...

At-home colon cancer tests aren’t the right option for people with a history of colon cancer or high-risk conditions, such as ...

CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug ...

Kraft Heinz plans to remove all artificial dyes from its U.S. products by 2027 amid the Trump administration's push to remove ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Kraft said that it will instead use natural colors for impacted products sold under brands including Crystal Light, Kool Aid, ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by ...

Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new ...